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Psoriasis is one of man’s commonest in£ammatory dermatoses,
and the ability to manage it in all its clinical diversity is an im-
portant component of a dermatologist’s specialist skills. The tools
needed to do so include, crucially, a sound knowledge of how the
many di¡erent treatments used in psoriasis compare with each
other in terms of e⁄cacy, side-e¡ects and patient acceptability.
The EDEN (European Dermato-Epidemiology Network) sur-
vey of randomized controlled trials (RCTs) in psoriasis by Naldi
and colleagues in this issue of the Journal highlights how de¢cient
our collective knowledge is. The authors acknowledge that their
survey does not attempt to be comprehensive, in that they
restricted themselves to RCTs of psoriasis management published
in the last quarter of the twentieth century (1977^2000) in 14
leading general medical and dermatological journals from Europe
and North America. This strategy would have missed over 20%
of the 111 RCTs that we were able to ¢nd for a recent systematic
review of treatments for severe psoriasis (Gri⁄ths et al, 2000). In
contrast to a traditional review, however, the EDEN survey in-
volved hand-searching every volume of the selected journals to
ensure that no relevant trials were missed. Each trial was then
analyzed in detail for quality of design, execution and reporting.
Their survey thus gives us the opportunity to review the perfor-
mance of the dermatology community over the past quarter cen-
tury and its e¡orts to evaluate treatments for psoriasis.
The survey tells us many things we already know: much of
current practice has not been subject to rigorous evaluation; there
are few trials comparing di¡erent treatment modalities; few stu-
dies address long-term management; the patient’s view is rarely
considered. The major stimulus to new studies is from the phar-
maceutical industry, which was involved in sponsoring over 60%
of the 226 RCTs examined. Thus, although methotrexate is a
mainstay of treatment for severe psoriasis in many countries, it is
of little commercial interest and no RCT comparing it either
with placebo or with other therapies was found. Only two RCTs
comparing two or more di¡erent systemic treatments were
found. Psoriasis is a chronic condition that may last throughout
a patient’s lifetime, but the median duration of treatment in the
studies examined was only seven weeks. Under four per cent of
studies considered maintenance of remission over time or relapse
rates. Less than 10% of the studies reported patients’ preferences or
satisfaction with treatment and only one paper assessed quality of
life issues. Forty-three di¡erent scoring systems were used to
assess outcome in the RCTs examined! The authors found no
di⁄culty in ¢nding methodological £aws in the execution,
analysis and reporting of studies, particularly with regard to
blinding procedures and handling of drop-outs.
RCT evidence is not the only means of learning about the
relative bene¢ts and harms of di¡erent therapies for psoriasis.
Carefully conducted cohort studies can be invaluable in detecting
and quantifying harm, as in the work of Stern and colleagues
(Stern et al, 1998) in photochemotherapy-induced skin malig-
nancy and of investigators such as Roenigk and Zachariae in
methotrexate-induced liver damage (Zachariae et al, 1996;
Roenigk et al, 1998). To be able to give informed advice to our
patients, however, we need to have unbiased evidence not only
of e⁄cacy but also of relative merit, and such evidence is best
obtained from well-conducted RCTs.
The authors of the current survey correctly point out that the
interests of people with psoriasis are poorly served by the existing
corpus of evidence from RCTs.We came to similar conclusions in
our review of treatments for severe psoriasis (Gri⁄ths et al, 2000),
though that is not to deny that much useful information can be
garnered from such a review. The most important message from
the current survey is contained in the authors’ recommendations
for improving the quality of design and reporting of future
psoriasis studies. Many of these issues are addressed in the
CONSORT statement about good practice in designing, analyz-
ing and reporting clinical trials (Begg et al, 1996; Cox and
Williams, 2000). The authors do, however, make a number of
other important points. Placebo-controlled trials should be lar-
gely con¢ned to early development of new therapies. Compari-
sons with standard practice should be performed before there is
wide acceptance of new treatments. More longer-term studies
more closely mirroring everyday clinical practice are needed in
order to assess patient acceptability and side-e¡ects. In order that
the results of studies are relevant to patients, people with psoriasis
should be consulted during the design stage to ensure that out-
comes important to them are measured.
There is, unfortunately, no consensus as to the best way to as-
sess response of psoriasis to treatment. It is obviously important
to be able to document changes in disease severity objectively.
Because most interventions have on their own been insu⁄cient
to induce clearance, a plethora of di¡erent assessment methods
has been devised. Only in phototherapy trials has it been custom-
ary to use simple measures such as ‘‘clearance’’ or ‘‘minimal resi-
dual activity’’. The most commonly used measure, the Psoriasis
Area and Severity Index (PASI), is not only cumbersome to cal-
culate and terminologically inaccurate (the terms ‘‘desquamation’’
and ‘‘in¢ltration’’ are used to score for ‘‘scale’’ and ‘‘epidermal
thickening’’, respectively); it is also poor at identifying changes
in mild-to-moderate psoriasis and takes no account of the psy-
chosocial impact of the disease (face and lower back are scored
equally). An international debate is required to reach some con-
sensus on measures of psoriasis severity which address these prob-
lems and which could then become standard for future studies.
The goal of patients is generally to achieve long-term disease
suppression with a minimum of risk and of side-e¡ects. If noth-
ing more than short-term reduction in objective severity scores
were taken into consideration, it would be a simple matter to
show superiority of, for instance, high dose systemic corticosteroids
over most other rivals. Dermatologists are, however, well aware
of their hazards both in general and in psoriasis in particular.
On the other hand, they may not be so alert to the dangers of
extrapolating the results of short-term trials of less familiar agents
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to the longer-term management of a chronic disease such as psor-
iasis. The ability of a particular treatment to produce a signi¢cant
change in a severity score, however sophisticated, does not neces-
sarily translate to a healthy or to a satis¢ed patient.What is clear
from Naldi’s survey is that a range of relevant and easily interpre-
table outcome measures including, crucially, the views of the pa-
tient is required. Subtle di¡erences in complex disease severity
scores are likely to be of less interest to the patient than simple
outcomes which can be applied to all patients, e.g., ‘‘Is my psoria-
sis worse, unchanged, better or clear?’’or ‘‘Is the treatment worth-
while?’’ (i.e., ‘‘Do the bene¢ts achieved outweigh the costs, risks,
inconvenience and side-e¡ects of treatment?’’).
Appropriate selection and categorization of patients for RCTs
is just as important as appropriate use of outcome measures. As
we learn more about the immunogenetics of chronic plaque psor-
iasis (seven susceptibility loci described to date) it becomes clearer
that the interactions between genes and the environment respon-
sible for variations in phenotypic expression and behavior of
psoriasis are likely to be highly complex. Our dermatological
forefathers were reliant purely on clinical skills and were able to
classify and subclassify diseases such as psoriasis based on clinical
features alone. Perhaps with the bene¢t of hindsight we should
be returning to this clinical skill level and stratify/classify our pa-
tients to appreciate better the di¡erent subtypes of chronic plaque
disease and by implication diverse responses to therapy, in essence
aligning pharmacogenetics to phenotypic analysis.We have also
previously highlighted the importance of taking into account
psychosocial disability and previous responses to therapy in doc-
umenting psoriasis severity (Kirby et al, 2000). The importance of
this is exempli¢ed by a recent study in which we demonstrated
that psychological distress signi¢cantly reduces the probability
that psoriasis will respond to photochemotherapy (Fortune et al,
2003). There is thus scope for improving the power of psoriasis
studies by stratifying for such factors in the design of treatment
allocation protocols.
Encouragingly, there are signs that both healthcare funding or-
ganizations and dermatologists are beginning to address some of
the issues highlighted by Naldi and colleagues. Since 1993, the
United Kingdom Department of Health, through its Research
and Development Health Technology Assessment Programme,
has been funding projects to help identify important knowledge
gaps about clinical and cost e¡ectiveness of interventions for a
wide range of diseases including psoriasis (Gri⁄ths et al, 2000)
and atopic dermatitis. The Cochrane Skin Group, founded in
1997 by interested dermatologists including several of the authors
of the current survey, has been producing reviews of therapeutic
interventions for skin disease for the Cochrane Library (Williams
et al, 1998). The ¢ndings of such reviews can be highly in£uential
in persuading funding bodies to support studies that would have
little attraction for the pharmaceutical industry. Thus the Dutch
Government recently funded a study comparing methotrexate
with ciclosporin for psoriasis (Heydendael et al, 2002). Dermatol-
ogists in the UKwith an interest in clinical research and clinical
trials have formed the UK Dermatology Clinical Trials Network.
The philosophy behind this group is that a network of such like-
minded individuals could design and administer adequately pow-
ered studies and, by acting as a consortium, facilitate studies not
fundable by industry. Our view is that such an enterprise should
not necessarily be limited to the UK but could be international ^
perhaps a logistical problem, but a surmountable and a worthy
goal.
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